Skip to main content
. 2016 Oct 26;8(12):899–907. doi: 10.14740/jocmr2773w

Figure 1.

Figure 1

In vitro antithrombotic effects (AR-AUC (a) and PL-AUC (b)) in the absence of (control) or presence of (spiked) rivaroxaban and apixaban in blood from healthy volunteers using AR-chips and PL-chips. *P < 0.05 vs. control.